drugset / Trial / NCT03085966

Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

NCT03085966

Phase 1/2 Unknown 30 enrolled Shanghai AbelZeta Ltd. Fudan University · collab
NaSingle-groupOpen-labelTreatment

Summary

Study of autologous immune cell therapy in combination with the luteinizing hormone releasing hormone agonists (LHRH-a) in patients with metastatic castration-resistant prostate cancer

Timeline

Start
2017-02-27
Primary completion
2019-10-27
Completion
2019-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous dendritic cells Cell therapy
Subject central memory T cells Unknown